NVCR
NovoCure Limited
$17.96
+0.06
(+0.34%)
Mkt Cap
2.08B
Volume
801,321
52W Range
9.82-20.06
Sector
Healthcare
Beta
0.90
EPS (TTM)
-1.53
P/E Ratio
-10.58
Revenue (TTM)
674.41M
Rev Growth (5Y)
+5.8%
EPS Growth (5Y)
N/A
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 655.35M | 605.22M | 509.34M | 537.84M | 535.03M | 494.37M | 351.32M | 248.07M | 177.03M | 82.89M | 33.09M | 15.49M |
| Net Income | (136.23M) | (168.63M) | (207.04M) | (92.53M) | (58.35M) | 19.81M | (7.23M) | (63.56M) | (61.66M) | (131.84M) | (111.58M) | (80.68M) |
| EPS | -1.22 | -1.56 | -1.95 | -0.88 | -0.56 | 0.20 | -0.07 | -0.69 | -0.70 | -1.54 | -1.34 | -1.12 |
| Free Cash Flow | (75.68M) | (69.22M) | (100.43M) | 9.43M | 58.59M | 84.18M | 16.14M | (8.58M) | (40.50M) | (125.26M) | N/A | N/A |
| FCF / Share | -0.68 | -0.64 | -0.94 | 0.09 | 0.57 | 0.83 | 0.17 | -0.09 | -0.46 | -1.46 | N/A | N/A |
| Operating CF | (49.03M) | (26.37M) | (73.34M) | 30.79M | 82.76M | 99.15M | 26.62M | (1.86M) | (33.13M) | (107.59M) | N/A | N/A |
| Total Assets | 804.33M | 1.24B | 1.15B | 1.19B | 1.14B | 1.05B | 479.45M | 339.79M | 265.30M | 282.08M | N/A | N/A |
| Total Debt | 290.00M | 683.35M | 596.24M | 584.27M | 581.90M | 450.68M | 168.20M | 149.27M | 97.34M | 96.23M | N/A | N/A |
| Cash & Equiv | 103.39M | 163.77M | 240.82M | 115.33M | 209.61M | 246.17M | 179.42M | 140.62M | 78.59M | 99.78M | N/A | N/A |
| Book Value | 340.47M | 360.18M | 362.50M | 441.17M | 410.49M | 476.53M | 217.79M | 112.26M | 113.56M | 142.34M | N/A | N/A |
| Return on Equity | -0.40 | -0.47 | -0.57 | -0.21 | -0.14 | 0.04 | -0.03 | -0.57 | -0.54 | -0.93 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 174.06M | 174.35M | 167.20M | 158.81M | 154.99M | 161.27M | 155.09M | 150.36M | 138.50M | 133.78M | 127.32M | 126.05M |
| Net Income | (71.14M) | (24.50M) | (37.27M) | (40.14M) | (34.32M) | (65.92M) | (30.57M) | (33.38M) | (38.76M) | (47.08M) | (49.48M) | (57.42M) |
| EPS | -0.62 | -0.22 | -0.33 | -0.36 | -0.31 | -0.61 | -0.28 | -0.31 | -0.36 | -0.44 | -0.46 | -0.54 |
| Free Cash Flow | (18.67M) | (22.90M) | 14.92M | (21.42M) | (46.28M) | (12.39M) | (307,000) | (13.17M) | (43.36M) | (21.38M) | (26.57M) | (29.67M) |
| FCF / Share | -0.16 | -0.21 | 0.13 | -0.19 | -0.42 | -0.11 | -0.00 | -0.12 | -0.40 | -0.20 | -0.25 | -0.28 |
| Operating CF | (13.52M) | (18.00M) | 20.57M | (15.94M) | (35.66M) | (3.45M) | 10.38M | (1.72M) | (31.57M) | (14.56M) | (19.31M) | (22.74M) |
| Total Assets | 787.93M | 804.33M | 1.36B | 1.25B | 1.25B | 1.24B | 1.22B | 1.21B | 1.12B | 1.15B | 1.15B | 1.16B |
| Total Debt | 234.94M | 290.00M | 797.94M | 700.25M | 696.73M | 683.35M | 675.63M | 675.20M | 595.26M | 596.24M | 590.04M | 587.48M |
| Cash & Equiv | 97.32M | 103.39M | 344.64M | 149.62M | 127.28M | 163.77M | 185.42M | 168.44M | 453.76M | 240.82M | 154.86M | 156.98M |
| Book Value | 330.72M | 340.47M | 341.33M | 349.44M | 361.96M | 360.18M | 360.78M | 361.75M | 359.36M | 362.50M | 393.70M | 415.68M |
| Return on Equity | -0.22 | -0.07 | -0.11 | -0.11 | -0.09 | -0.18 | -0.08 | -0.09 | -0.11 | -0.13 | -0.13 | -0.14 |
NVCR News
3 Overlooked Stocks Set to Soar in 2026
International Markets and NovoCure (NVCR): A Deep Dive for Investors
NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet
NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
Novocure Reports First Quarter 2026 Financial Results
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Hold” by Analysts
Head to Head Contrast: NovoCure (NASDAQ:NVCR) versus Alterity Therapeutics (NASDAQ:ATHE)
JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR
Novocure to Report First Quarter 2026 Financial Results